Triumeq: Partial Dispensing, Unit-Dose Repackaging, and Temperature Stability



Storage, Partial Dispensing, and Unit-Dose Packaging



Triumeg (abacavir/dolutegravir/ lamivudine [ABC/DTG/3TC]) tablets should be stored and dispensed in the original package, protected from moisture, and with the bottle tightly closed. Do not remove the desiccant from the bottle.1



ABC/DTG/3TC tablets are moisture-sensitive and the product stability is linked to the presence of moisture. ABC/DTG/3TC tablets should not be repackaged into unitdose blister packages.



Once opened, ABC/DTG/3TC tablets may be dispensed up to the expiration date that is stamped on the container, as long as the desiccant is present and still intact.



ViiV Healthcare cannot recommend the use of product that is stored or dispensed outside of the original packaging or product that has been stored without the desiccant.

Supplemental Temperature Stability Data



The following studies were conducted in HDPE bottles with child resistant closures and induction seal liners. The bottles contained 30 tablets and included a two-gram silica gel desiccant. This container is identical to the commercial HDPE bottle used to ship and store ABC/DTG/3TC tablets.2



High Temperature Stability

- Studies that evaluated temperature stability excursions showed that ABC/DTG/3TC was stable at 30° C (86° F) and 75% RH for up to 36 months.²
- Further data indicated that temperatures of 40° C (104° F) / 75% RH for up to 6 months and temperatures of 50° C (122° F) at ambient humidity for up to 3 months found no significant change in stability.2













Low Temperature Stability

A 28-day freeze-thaw study evaluated ABC/DTG/3TC under alternating freezing conditions of -20° C (-4° F) for seven days, then 30° C (86° F) for seven days (two cycles each), found no significant change in stability.2



Important safety information is found in the Prescribing Information.

For more information



MI Letter









CLICK FOR VIIV US Medical Portal

This information is scientific and non-promotional in nature and is not intended for further distribution. This information is not intended to offer recommendations for using this product in a manner inconsistent with its approved labeling. Please consult the Prescribing Information. For ViiV Healthcare to monitor the safety of our products, we encourage healthcare professionals to report adverse events or suspected overdoses to the company at 877-844-8872. Selection of references follows principles of evidence-based medicine and, therefore, references may not be all inclusive.

Abbreviations: ABC/DTG/3TC = Abacavir/dolutegravir/lamivudine: HDPE = High-density polyethylene: MI = Medical information: RH = Relative humidity. References: 1. ViiV Healthcare. Global Data Sheet for dolutegravir-abacavir-lamivudine, Version 18, Nov 11, 2022. 2. Data on File. 2015N244026.